Pseudoexfoliation (PEX) is a common disorder and the most common cause of secondary glaucoma. Despite this, not all subjects with PEX will develop glaucoma.1 According to epidemiological studies, only 15%-30% of subjects with PEX have developed glaucoma.2 Gene variants of LOXL1 do not help identify those with PEX at increased risk of glaucoma.2 Although the presence of PEX is not directly included in the risk calculation formula for glaucoma in subjects with ocular hypertension (OHT), the risk for glaucoma in subjects with PEX and OHT is three times higher than in those with similar high IOP (>21 mmHg) but without PEX.3 Therefore, the management of OHT in the co-existence of PEX should be more intensive. In addition, in individuals who have already developed pseudoexfoliative glaucoma, the rate of progression is also three times higher compared to that in those with primary open-angle glaucoma.4 More aggressive treatment options (Lower target IOP, closer follow-ups and glaucoma surgery) are deemed necessary to mitigate the relative risk of progression to blindness in those patients.
References
Contributor: Eleftherios Anastasopoulos, MD, PhD Glaucoma specialist, AXEPA Hospital, Thessaloniki, Greece
Tip of the Month Manager: Karin Øyo-Szerenyi
Tip of the Month Editors: Karl Mercieca, Francisco Goñi
Tip of the Month Editors in Chief: Manuele Michelessi, Francesco Oddone